Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/56860
THE DOUBLE FACE OF MIR-708: A PAN-CANCER PLAYER WITH DISSOCIATIVE IDENTITY DISORDER
Author
Affilliation
Universidade Federal do Paraná. Departamento de Genética. Curitiba, PR, Brasil.
Universidade Federal do Paraná. Departamento de Genética. Curitiba, PR, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciências e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil.
Faculdade Anhanguera. Departamento de Biotecnologia e Inovação em Saúde. Pirituba, SP, Brasil.
Faculdade Anhanguera. Departamento de Biotecnologia e Inovação em Saúde. Pirituba, SP, Brasil.
Universidade de São Paulo. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto. Departamento de Biologia. Ribeirão Preto, SP, Brasil.
Universidade Federal do Paraná. Departamento de Genética. Curitiba, PR, Brasil. / Fundação Oswaldo Cruz. Instituto Carlos Chagas. Laboratório de Ciências e Tecnologias Aplicadas em Saúde. Curitiba, PR, Brasil.
Faculdade Anhanguera. Departamento de Biotecnologia e Inovação em Saúde. Pirituba, SP, Brasil.
Faculdade Anhanguera. Departamento de Biotecnologia e Inovação em Saúde. Pirituba, SP, Brasil.
Universidade de São Paulo. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto. Departamento de Biologia. Ribeirão Preto, SP, Brasil.
Abstract
Over the last decades, accumulating evidence has shown tumor-dependent profiles of miR708, being either up- or downregulated, and thus, acting as a “Janus” regulator of oncogenic pathways. Herein, its functional duality was assessed through a thorough review of the literature and further validation in silico using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. In the literature, miR-708 was found with an oncogenic role in eight tumor types, while a suppressor tumor role was described in seven cancers. This double profile was also found in TCGA and GEO databases, with some tumor types having a high expression of miR-708 and others with low expression compared with non-tumor counterparts. The investigation of validated targets using miRBase, miRTarBase, and miRecords platforms, identified a total of 572 genes that appeared enriched for PI3K-Akt signaling, followed by cell cycle control, p53, Apellin and Hippo signaling, endocrine resistance, focal adhesion, and cell senescence regulations, which are all recognized contributors of tumoral phenotypes. Among these targets, a set of 15 genes shared by at least two platforms was identified, most of which have important roles in cancer cells that influence either tumor suppression or progression. In a clinical scenario, miR-708 has shown to be a good diagnostic and prognosis marker. However, its multitarget nature and opposing roles in diverse human tumors, aligned with insufficient experimental data and the lack of proper delivery strategies, hamper its potential as a sequence-directed therapeutic.
Share